<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-023021
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060531
<FILING-DATE>20060531
<DATE-OF-FILING-DATE-CHANGE>20060531
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06875610
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v044571_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of May 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-51122</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              May 31,
              2006</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><em>Company
              Secretary</em></font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="85%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Directors to take up Entitlements under the Rights
                Issue</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="85%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v044571_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="psividalogo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><strong><font size="2">ASX/MEDIA
                RELEASE</font></strong></div>
            </td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;<strong><font size="2">30
                May
                2006</font></strong></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"></font>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Arial, sans-serif"><strong>pSivida
      Directors to take up Entitlements under </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Arial, sans-serif"><strong>the
      Rights Issue</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. and Perth, Australia - Global bio-nanotech company pSivida Limited
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      pleased to announce that the Directors of the Company have confirmed that they
      will be taking up rights to subscribe for pSivida shares under their respective
      individual eligible entitlements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capital
      raised from this Rights Issue will primarily fund the phase III clinical trials
      of Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for the
      treatment of Diabetic Macular Edema (DME), and phase IIa clinical trials of
      our
      lead BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      product,
      BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      which is
      being developed for the treatment of inoperable pancreatic cancer.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Rights Issue is on a non-renounceable 1 for 8 basis to raise approximately
      A$29
      million at A$0.60 per ordinary share, and has an incorporated top up facility
      whereby eligible shareholders may apply for additional new ordinary shares
      in
      excess of their entitlement at the same price. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Rights Issue is not underwritten. To the extent there is any shortfall under
      the
      Rights Issue, pSivida has agreed to place such shortfall through Janney
      Montgomery Scott LLC, the U.S. based Lead Manager for this issue, to
      institutional and sophisticated investors. Any ordinary shares issued in the
      U.S. in connection with the Rights Issue as a result of any shortfall will
      be
      issued in a private placement. These shares will not be registered under the
      U.S. Securities Act of 1933, as amended, or any U.S. state securities laws
      and
      may not be offered, sold or transferred in the U.S. absent registration or
      an
      applicable exemption form registration requirements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Record Date for the Rights Issue was 22 May 2006. The ordinary shares to be
      issued in connection with the Rights Issue are expected to commence trading
      on
      the Australian Stock Exchange on 8 June 2006. Applications will close on 7
      June
      2006. The period for placement of the shortfall is expected to be between 7
      and
      13 June 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      ordinary shares issued in the U.S. in connection with the Rights Issue as a
      result of any shortfall will be issued in a private placement. These shares
      will
      not be registered under the U.S. Securities Act of 1933, as amended, or any
      U.S.
      state securities laws and may not be offered, sold or transferred in the U.S.
      absent registration or an applicable exemption form registration
      requirements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a treatment
      for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
      III
      clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      pSivida
      conducts its operations from offices and facilities near Boston in the United
      States, Malvern in the United Kingdom, Perth in Australia and Singapore.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and on
      the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in 2001 from
      the
      UK Government's Defence Evaluation &amp; Research Agency (DERA). QinetiQ (QQ.)
      was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with, including access to its cutting
      edge
      research and development facilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases. Although
      we
      believe that the expectations reflected in such forward-looking statements
      are
      reasonable at this time, we can give no assurance that such expectations will
      prove to be correct. Given these uncertainties, readers are cautioned not to
      place undue reliance on such forward-looking statements. Actual results could
      differ materially from those anticipated in these forward-looking statements
      due
      to many important factors including: failure to complete negotiations for new
      centers for the BrachySil&#8482; phase IIb clinical trial for inoperable primary liver
      cancer; the failure of our discussions with the FDA for BrachySil&#8482; to continue
      or to lead to FDA approval; the failure of the BrachySil&#8482; phase IIb clinical
      trial for inoperable primary liver cancer to determine the optimal dose, provide
      key safety data or support future pivotal efficacy trials or product
      registration or approval; failure to commence Phase IIa BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      for the treatment of pancreatic cancer; the failure of the results of the
      Retisert&#8482; for DME trial to be a good indicator of the results of pSivida&#8217;s
      ongoing Phase III Medidur&#8482; for DME trial; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      in DME to show a very similar improvement in visual acuity and diabetic
      retinopathy severity score as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      DME</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
      inability to recruit patients for the Phase III Medidur&#8482; for DME trial; our
      failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      pSivida Inc&#8217;s operations and employees; the failure of the pSivida Inc&#8217;s
      products to achieve expected revenues and the combined entity&#8217;s inability to
      develop existing or proposed products; the failure of the Bausch &amp;
Lomb/Novartis co-promotion arrangement to provide faster royalty growth; failure
      of the slower progression or reduction of diabetic retinopathy resulting from
      the Retisert&#8482; implant to have significant implications for Retisert&#8482; and
      Medidur&#8482;; failure of our evaluation agreements to result in license agreements;
      failure of Medidur&#8482; to release the same drug as Retisert&#8482; at the same rate;
      failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;
trials
      in DME to show a very similar stabilization or improvement diabetic retinopathy
      as Retisert&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      DME;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      failure
      to achieve cost savings; failure to execute on US growth strategy; failure
      of
      the findings&#160;of the pancreatic cancer phase IIa trial to provide a platform
      for further multicentre efficacy and safety trials; failure of there to be
      optimisation&#160;and standardisation between the two&#160; pancreatic
      cancer&#160;study&#160;centres; failure of the BrachySil&#8482; primary liver
      programme that is in Phase IIb clinical trials to&#160;provide a valuable
      platform for the development and commercialisation of BrachySil&#8482; for pancreatic
      cancer and other indications</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      reasons are contained in cautionary statements in the Annual Report on Form
      20-F
      filed with the U.S. Securities and Exchange Commission, including, without
      limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to
      update any oral or written forward-looking statements that may be made by or
      on
      behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psividalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psividalogo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0TC17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHP-3HS
M,2`P,SHP,CHP,````````Z`!``,````!``$``*`"``0````!```!3Z`#``0`
M```!````<``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```OM````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`-0"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]5223%)2Z2HLZG7ZS:+V.HL=HT.+3KVW
M;'.V;OY2GD]0KQG$65V%HC](ULMU[;I4'WO!PRGQ@1@>&=@C@E_7C\T4T6VJ
MG4>J8'2\<Y/4+V8U(,!SSJ3^Y6SZ=MG_``=?O5>SJ5N54ZOIP=7>8:VZVHV5
ML)_.L9796YW_`&XJ>-T_$Z=E-MRGV=6ZQ8).3<6RV?S,6IQ;1A5/=]&G'_2/
M_P`)ZJ(YK`8>X)@POAL=9'I']Y!$KH#[6.3]8>L_9;L[$Z0YN'CL=:Y^;:,>
MQ[&`N?Z6*VO(M9[6^S[5Z"V.GYC,[`QLZMI:S*J9<UKOI`6-%C6N_P`Y9G5M
M_5BSHC&N;7=M?U5P,>G1_.?8]['?S^=M]'8WZ&)Z]O\`W']7::UK&AK0&M:(
M`&@`'93`@@%;&[.MC_NF2228D`2=`$ERZ2IGJO3PZ/6'Q`)'^=&U66O:]H<P
MAS7:APU!'DH\>?%D)&/)&9&_!*,^'SX4D$;AFDJN+U"C*L?75NW,U.X1WVJR
MCCRPR1XH2$H[6/!!%;KI)BLKH?UEZ=URS*KPA8'89:VWU&AHEQL8W9#G;OYA
MZ>@D`@$ZG9UDDEG8G7^D9G4+NFXV0+,S'W^K4&N!;Z;A5;[G-:SV6.V_2242
M!5FKV=%))))+_]#U5,4Z8I*<?K9;[@3#MK7-&X>);_-[]W_@2K9'63GNS,2B
MAQQL(-9?FDPPY(?7NQ*6$?I?38YSKK?H5_S:,_J(ZIU/(Z;AU&VK"86Y>87D
M4MO):6X&UG\_;Z?OO<UWZI_X&FROVG5A&C(8TT-VCU`9(@C9W_[XL?FHRPGF
MR82E#/B-2@.*,)#C_G.'Y?YQ?$B7#1^4Z^*?H'\W=_6'Y$/'?OZI=)]QM@#<
M!HR?S=['/^C^Y8@]-?GBNQN&QKMQ&Y[B)!C2`7+1Z=@VX\NN(WG4!KG'4_2>
M_=[=_P#847)B>;#R>.,)".(RR9)RCPX_TJC"7Z7S+I:&7BW*ZJZP=C0W<2YT
M=W'EQ5#ZP]6=T;I%_4FU"\T%@](NV3O>RGZ>VSZ/J?N+17/_`%^_\2>9\:/_
M`#_2MT;M?(2(2(W$27*R/K]U)N!5U*GHK_L#MK7Y-ENUOJ$>]E6VMS_1;;^B
MKRGL].U;S>HCJOU=9U#':YC<BL/=6=2V';;V3_(VO7.Y/_Y*F3_H:?\`S_6M
M;ZE7U4?5#`?<\,;^E`)\?5NT3.8A&6')$RX!*,H&?[O%'YF/#.?NQ!/%>,9-
MNMIL"C!R:'4O(;E$DM<>?Y!K_D_OL6G@8;L.HU&SU`3(T@"?I!NKE1RNG8M^
M.<O#(:V"[;!#3'TMK7?S3O:K'1LJV^I[+3N=40`X\D'C=_FK)Y&,,.?%BR8X
MC+[9]CF,)_5Y\7S>H?O-N1L$@Z7J#T6Z?ELONN8S'92YH^DWOJ6^Z&M6;]5_
MK8_KN3EXE^(,+(Q(E@L]23N?5=_@Z=OHV,_Z:M=%_I>1\/\`OSEQW4<E_P!6
M?KMU#)K]C,O'MMKW:RZYAN9_G=1QMBN_"\DLO+"4S<N*?01^67]5@YF1QRA+
M:%U+_">K^KOUG?US/SZ&8PJQL%VUN0+"\V2^RNO]'Z;-FZNKU/YQ`^I_6<3J
MF1U)F/TVGIQQGL#W4EI-I<Z]NZS953]'TOY?\ZH?XN.G_9?JZW(/T\VQ]I)Y
MVM_5ZO\`.;5ZO_75F_XM?Z9US_C*O^KRU=[^#%&<_P!3Q?I\1/\`B\46]D?7
M7-?US(Z5TGI;NH'$+A:X6BMQ].!<YH<S8UM=I]+WO_2O6/\`4F[[1]=NI9&Q
M]7K,R;/2L&VQFZ^E_IVL_,M9]%ZL?4O_`,6?73WWW_\`MRY#^J7_`(O^L?\`
MH7_[<5(]#Y,7%*4L<I&_UDA7DZ?4?KU<WK%O2.C].=U'(I)8]P?M&]G\\UK&
ML?[*7?HWVV/J_2JW]5_K>WKN1?A78IP\O';O-9<7`M#O2M^DRI]=E-OLLK>U
M9>3U^_)ZY=TWZH]/QOM8+VY74K&!HG=^L.FL-=Z;;?\`#6>IZ]O\UCV_SBH_
M49M[/KIU-F2\6Y#:\EM]@$!U@R*1;8UOYK7V>Y*M"O\`<E[D0)<0E(Q.GH_P
M2__1]46+]9>H7UUX_2<!Q9U'JSS138WFJL"<S.Y;_1:7?HO?_/\`I+:*Y+*^
ML?1\+ZQ6V=6JOQNH8C+,;&#*W6LOHN=5?7;3Z;7?I=U7I_\`;G_6TLR2`%$U
M>EO2=-Z=B=,P:<##8*\?':&UM[^+G//YUCW>^Q_[ZK?6#*QL;ISG9%@K#WL9
M6#)<]Y=[:Z:V!UEUKO\`1UMWJA7UCZQ]3='3.F?8,8_]K.I>UWGZ?3Z3ZS_Y
M'J75*QB?5JFFPY>3DW9G4G@A^=81O:T_2IQ&;?2PJ-?H8S=_^DML4?,8_<PY
M(&SQQE'TZ2]7I_23&6HX1IW/R_\`H2W069+Q:ZP&BL.'Z`QZA,?2R'-<ZNO_
M`,+,_2?Z>S_`+:"I8_2JL=P=5;:T`@EH<-ICL\;5='"BY+'/'ACCE`8^"P`)
M<?IOB^9>=][77/?7[_Q)YGQH_P#/]*Z%4>K]*Q^K]/MZ?DN>RFXM+G5$!WL<
MVYL%S7M^DS]U61NQY(F4)1&Y!#PN)]6?K)U7ZMX56'U%AZ;>T6OQ+Y;L>''1
MEE5;[+:-_P"D92]_TUVW3>BT8/1:.D%QLKJKV.LC:2Z=[[0W79^E=O:C]+Z=
M1TO`HP,=SW4X[=C'6$%Q$[O<6M8WO^ZK:4P)1,9`&,@00>HDC%B$*.O%0CO=
M5^ZXAZ/GM#JJ[V^BXR1+FS_6K$K2P<-F)5L!W.<=SW<2?A^ZK*2J8.0P8)\<
M`>(#ACQ2,_;B?T8<7RLQF2*+G=/Z?;BWVV/<UPL&@;/[Q=W6-]<_JGE=>LQ;
M\*RFJVAMC+#=N&YKMKZH]-K_`.;>U_\`VXNJ24V###!`0Q@B().IOYO4LR1&
M0&,M06KTS$.#TW$PR0XXU-=1<."6-;67#^MM6)]4?JUF]#R.HVY5M5C<U['5
MBK=(#77O_2;VM_T[5TJ2EM'!&XG]S;_HO%Y?U/Z[C_6"_JG0L^K$9F%SKC8"
MY[/4(=>UM3F657M=8WUJ]WHJQ]7?JCF]'^L&3U*S);D8]M=C&%SG.O<ZQ]5O
MJY#BQK-[G5V;UUB2-E8,$`;%Z'B&N@+P=/U)^LG3.J9%_1.HTXV-D%P-CP38
M*W.]38^AU=E5CZ=WZ.SU*_\`K>]7_JQ]4,_HO7<G/NR*\BBVNRMCI<;B7V56
MMLNW-V;W>F[U?=]-=:DE94,$`01>AXAKH+?_TO54R^5DDE/U2G7RJDDI^JDE
M\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)
M*?JI)?*J22G_V?_M$<!0:&]T;W-H;W`@,RXP`#A"24T$)0``````$```````
M```````````````X0DE-`^T``````!``2`````$``0!(`````0`!.$))300F
M```````.`````````````#^````X0DE-!`T```````0```!X.$))3009````
M```$````'CA"24T#\P``````"0```````````0`X0DE-!`H```````$``#A"
M24TG$```````"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8`
M``````$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0``
M``$`+0````8```````$X0DE-`_@``````'```/______________________
M______\#Z`````#_____________________________`^@`````________
M_____________________P/H`````/____________________________\#
MZ```.$))300(```````0`````0```D````)``````#A"24T$'@``````!```
M```X0DE-!!H``````TD````&``````````````!P```!3P````H`50!N`'0`
M:0!T`&P`90!D`"T`,0````$``````````````````````````0``````````
M```!3P```'```````````````````````0`````````````````````````0
M`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T
M,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M
M;&]N9P```'``````4F=H=&QO;F<```%/````!G-L:6-E<U9L3',````!3V)J
M8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R
M;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@``
M``UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````
M26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```!P`````%)G
M:'1L;VYG```!3P````-U<FQ415A4`````0```````&YU;&Q415A4`````0``
M`````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L
M;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R
M>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV
M97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````
M"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE
M````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG````````
M``QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<`````
M`#A"24T$*```````#`````$_\````````#A"24T$%```````!`````(X0DE-
M!`P`````#`D````!````H````#4```'@``!C8```"^T`&``!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`#4`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54DDQ2
M4NDJ+.IU^LVB]CJ+':-#BTZ]MVQSMF[^4IY/4*\9Q%E=A:(_2-;+=>VZ5!][
MP<,I\8$8'AG8(X)?UX_-%-%MJIU'JF!TO'.3U"]F-2#`<\ZD_N5L^G;9_P`'
M7[U7LZE;E5.KZ<'5WF&MNMJ-E;"?SK&5V5N=_P!N*GC=/Q.G93;<I]G5NL6"
M3DW%LMG\S%J<6T853W?1IQ_TC_\`">JB.:P&'N"8,+X;'61Z1_>01*Z`^UCD
M_6'K/V6[.Q.D.;AX['6N?FVC'L>Q@+G^EBMKR+6>UOL^U>@MCI^8S.P,;.K:
M6LRJF7-:[Z0%C18UKO\`.69U;?U8LZ(QKFUW;7]5<#'IT?SGV/>QW\_G;?1V
M-^AB>O;_`-Q_5VFM:QH:T!K6B`!H`!V4P((!6QNSK8_[IDDDF)`$G0!)<NDJ
M9ZKT\.CUA\0"1_G1M5EKVO:',(<UVH<-01Y*/'GQ9"1CR1F1OP2C/A\^%)!&
MX9I*KB]0HRK'UU;MS-3N$=]JLHX\L,D>*$A*.UCP016ZZ28K*Z']9>G=<LRJ
M\(6!V&6MM]1H:)<;&-V0YV[^8>GH)`(!.IV=9))9V)U_I&9U"[IN-D"S,Q]_
MJU!K@6^FX56^YS6L]ECMOTDE$@59J]G122222__0]53%.F*2G'ZV6^X$P[:U
MS1N'B6_S>_=_X$JV1UDY[LS$HH<<;"#67YI,,.2'U[L2EA'Z7TV.<ZZWZ%?\
MVC/ZB.J=3R.FX=1MJPF%N7F%Y%+;R6EN!M9_/V^G[[W-=^J?^!ILK]IU81HR
M&--#=H]0&2((V=_^^+'YJ,L)YLF$I0SXC4H#BC"0X_YSA^7^<7Q(EPT?E.OB
MGZ!_-W?UA^1#QW[^J72?<;8`W`:,G\W>QS_H_N6(/37YXKL;AL:[<1N>XB08
MT@%RT>G8-N/+KB-YU`:YQU/TGOW>W?\`V%%R8GFP\GCC"0CB,LF2<H\./]*H
MPE^E\RZ6AEXMRNJNL'8T-W$N='=QY<50^L/5G=&Z1?U)M0O-!8/2+MD[WLI^
MGML^CZG[BT5S_P!?O_$GF?&C_P`_TK=&[7R$B$B-Q$ERLCZ_=2;@5=2IZ*_[
M`[:U^39;M;ZA'O95MK<_T6V_HJ\I[/3M6\WJ(ZK]76=0QVN8W(K#W5G4MAVV
M]D_R-KUSN3_^2ID_Z&G_`,_UK6^I5]5'U0P'W/#&_I0"?'U;M$SF(1EAR1,N
M`2C*!G^[Q1^9CPSG[L03Q7C&3;K:;`HP<FAU+R&Y1)+7'G^0:_Y/[[%IX&&[
M#J-1L]0$R-(`GZ0;JY4<KIV+?CG+PR&M@NVP0TQ]+:UW\T[VJQT;*MOJ>RT[
MG5$`./)!XW?YJR>1C##GQ8LF.(R^V?8YC"?U>?%\WJ'[S;D;!(.EZ@]%NGY;
M+[KF,QV4N:/I-[ZEONAK5F_5?ZV/Z[DY>)?B#"R,2)8+/4D[GU7?X.G;Z-C/
M^FK71?Z7D?#_`+\Y<=U')?\`5GZ[=0R:_8S+Q[;:]VLNN8;F?YW4<;8KOPO)
M++RPE,W+BGT$?EE_58.9D<<H2VA=2_PGJ_J[]9W]<S\^AF,*L;!=M;D"PO-D
MOLKK_1^FS9NKJ]3^<0/J?UG$ZID=29C]-IZ<<9[`]U):3:7.O;NLV54_1]+^
M7_.J'^+CI_V7ZNMR#]/-L?:2>=K?U>K_`#FU>K_UU9O^+7^F=<_XRK_J\M7>
M_@Q1G/\`4\7Z?$3_`(O%%O9'UUS7]<R.E=)Z6[J!Q"X6N%HK<?3@7.:',V-;
M7:?2][_TKUC_`%)N^T?7;J61L?5ZS,FSTK!ML9NOI?Z=K/S+6?1>K'U+_P#%
MGUT]]]__`+<N0_JE_P"+_K'_`*%_^W%2/0^3%Q2E+'*1O]9(5Y.GU'Z]7-ZQ
M;TCH_3G=1R*26/<'[1O9_/-:QK'^REWZ-]MCZOTJM_5?ZWMZ[D7X5V*</+QV
M[S67%P+0[TK?I,J?793;[+*WM67D]?OR>N7=-^J/3\;[6"]N5U*Q@:)W?K#I
MK#7>FVW_``UGJ>O;_-8]O\XJ/U&;>SZZ=39DO%N0VO);?8!`=8,BD6V-;^:U
M]GN2K0K_`')>Y$"7$)2,3IZ/\$O_T?5%B_67J%]=>/TG`<6=1ZL\T4V-YJK`
MG,SN6_T6EWZ+W_S_`*2VBN2ROK'T?"^L5MG5JK\;J&(RS&Q@RMUK+Z+G57UV
MT^FUWZ7=5Z?_`&Y_UM+,D@!1-7I;TG3>G8G3,&G`PV"O'QVAM;>_BYSS^=8]
MWOL?^^JWU@RL;&Z<YV18*P][&5@R7/>7>VNFM@=9=:[_`$=;=ZH5]8^L?4W1
MTSIGV#&/_:SJ7M=Y^GT^D^L_^1ZEU2L8GU:IIL.7DY-V9U)X(?G6$;VM/TJ<
M1FWTL*C7Z&,W?_I+;%'S&/W,.2!L\<91].DO5Z?TDQEJ.$:=S\O_`*$MT%F2
M\6NL!HK#A^@,>H3'TLAS7.KK_P#"S/TG^GL_P"V@J6/TJK'<'56VM`():'#:
M8[/&U71PHN2QSQX8XY0&/@L`"7'Z;XOF7G?>UUSWU^_\2>9\:/\`S_2NA5'J
M_2L?J_3[>GY+GLIN+2YU1`=['-N;!<U[?I,_=5D;L>2)E"41N00\+B?5GZR=
M5^K>%5A]18>FWM%K\2^6['AQT9956^RVC?\`I&4O?]-=MTWHM&#T6CI!<;*Z
MJ]CK(VDNG>^T-UV?I7;VH_2^G4=+P*,#'<]U..W8QUA!<1.[W%K6-[_NJVE,
M"43&0!C($$'J)(Q8A"CKQ4([W5?NN(>CY[0ZJN]OHN,D2YL_UJQ*TL'#9B5;
M`=SG'<]W$GX?NJRDJF#D,&"?'`'B`X8\4C/VXG]&'%\K,9DBBYW3^GVXM]MC
MW-<+!H&S^\7=UC?7/ZIY77K,6_"LIJMH;8RPW;AN:[:^J/3:_P#FWM?_`-N+
MJDE-@PPP0$,8(B"3J;^;U+,D1D!C+4%J],Q#@]-Q,,D..-3747#@EC6UEP_K
M;5B?5'ZM9O0\CJ-N5;58W->QU8JW2`UU[_TF]K?].U=*DI;1P1N)_<V_Z+Q>
M7]3^NX_U@OZIT+/JQ&9A<ZXV`N>SU"'7M;4YEE5[76-]:O=Z*L?5WZHYO1_K
M!D]2LR6Y&/;78QA<YSKW.L?5;ZN0XL:S>YU=F]=8DC96#!`&Q>AXAKH"\'3]
M2?K)TSJF1?T3J-.-C9!<#8\$V"MSO4V/H=7958^G=^CL]2O_`*WO5_ZL?5#/
MZ+UW)S[LBO(HMKLK8Z7&XE]E5K;+MS=F]WIN]7W?376I)65#!`$$7H>(:Z"W
M_]+U5,OE9))3]4IU\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZ
MJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI_]D`.$))300A``````!3````
M`0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`
M;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P````$`.$))300&````
M```'``0````!`0#_X1?Z:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\
M/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"<_/@H\>#IX;7!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X
M.GAM<'1K/2=835`@=&]O;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\
M<F1F.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N
M8V]M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U
M=6ED.C$S,60X,V1D+68P-S,M,3%D82TY9C9A+3AB.#-B968P831B."<*("!X
M;6QN<SIE>&EF/2=H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@
M/&5X:68Z0V]L;W)3<&%C93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z
M4&EX96Q81&EM96YS:6]N/C,S-3PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@
M/&5X:68Z4&EX96Q91&EM96YS:6]N/C$Q,CPO97AI9CI0:7AE;%E$:6UE;G-I
M;VX^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TG=75I9#HQ,S%D.#-D9"UF,#<S+3$Q9&$M.68V82TX8C@S8F5F
M,&$T8C@G"B`@>&UL;G,Z<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O)SX*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2=U=6ED.C$S,60X,V1D+68P-S,M,3%D82TY9C9A+3AB.#-B
M968P831B."<*("!X;6QN<SIP:&]T;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\G/@H@(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H
M;W1O<VAO<#I(:7-T;W)Y/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z,3,Q9#@S9&0M9C`W,RTQ,61A
M+3EF-F$M.&(X,V)E9C!A-&(X)PH@('AM;&YS.G1I9F8])VAT='`Z+R]N<RYA
M9&]B92YC;VTO=&EF9B\Q+C`O)SX*("`\=&EF9CI/<FEE;G1A=&EO;CXQ/"]T
M:69F.D]R:65N=&%T:6]N/@H@(#QT:69F.EA297-O;'5T:6]N/C<R+S$\+W1I
M9F8Z6%)E<V]L=71I;VX^"B`@/'1I9F8Z65)E<V]L=71I;VX^-S(O,3PO=&EF
M9CI94F5S;VQU=&EO;CX*("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F
M.E)E<V]L=71I;VY5;FET/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z,3,Q9#@S9&0M9C`W,RTQ,61A
M+3EF-F$M.&(X,V)E9C!A-&(X)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,#8M,#4M
M,S%4,#,Z,#(Z,#`M,#4Z,#`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z36]D
M:69Y1&%T93XR,#`V+3`U+3,Q5#`S.C`R.C`P+3`U.C`P/"]X87`Z36]D:69Y
M1&%T93X*("`\>&%P.DUE=&%D871A1&%T93XR,#`V+3`U+3,Q5#`S.C`R.C`P
M+3`U.C`P/"]X87`Z365T861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O;VP^
M061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*
M(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.C$S,60X,V1D+68P-S,M,3%D82TY9C9A+3AB.#-B968P831B
M."<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
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M>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,
M10`!`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-
M4T94`````$E%0R!S4D="``````````````````#VU@`!`````-,M2%`@(```
M````````````````````````````````````````````````````````````
M$6-P<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($
M````%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0`
M``)4````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU
M;6D```/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(
M#&=44D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC
M*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S
M4D="($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ
M````````````````````````````````````````````````````````````
M``````!865H@````````\U$``0````$6S%A96B``````````````````````
M6%E:(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``
M```````DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C
M+F-H```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````
M`````````````````````````````````````````````````&1E<V,`````
M````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@````````````````````````````!D97-C````
M`````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``
M````$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%``
M``!7'^=M96%S``````````$````````````````````````"CP````)S:6<@
M`````$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`
M.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I
M`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!
M)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!
M`<D!T0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"
MC@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^
M`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$
MJ`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V
M!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'
MA@>9!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ
M"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+
M.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:
M#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/
MSP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D
M$H02HQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%305
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MPC7]-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO
M.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`
MID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G
M1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),
MNDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,3
M4U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:
M!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\
M84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]H
MEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K
M<(9PX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X
M;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H
M@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)
MF8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)Z
MDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<
M')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6I
MIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP
M`+!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[
MNK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%
M2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`Y
MT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<
M!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>I
MZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T
M-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N
M``Y!9&]B90!D``````'_VP"$``8$!`0%!`8%!08)!@4&"0L(!@8("PP*"@L*
M"@P0#`P,#`P,$`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!!P<'#0P-
M&!`0&!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`'`!3P,!$0`"$0$#$0'_W0`$`"K_Q`&B````
M!P$!`0$!```````````$!0,"!@$`!P@)"@L!``("`P$!`0$!``````````$`
M`@,$!08'"`D*"Q```@$#`P($`@8'`P0"!@)S`0(#$00`!2$2,4%1!A-A(G&!
M%#*1H0<5L4(CP5+1X3,68O`D<H+Q)4,T4Y*BLF-SPC5$)Y.CLS875&1TP]+B
M"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FYR=GI^2HZ2EIJ
M>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@#`VT!``(1`P0A$C%!!5$382(&<8&1
M,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,EHF.RP@=STC7B1(,75),("0H8&28V
M11HG9'15-_*CL\,H*=/C\X24I+3$U.3T976%E:6UQ=7E]4969G:&EJ:VQM;F
M]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZ
MBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NJ
M,5:Y#%5K31H"6/%1U)V&$!B9A3AO;68$PRK+3KP8-3[CC2B05N0P,F\5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_
M`/_0]4XJ[%78J[%78J[%78J[%78J[%7'H<50M[?6EE;/<7<J001BKR.P513?
M<G"-V,I`"R\MUS\ZY[_4&TCR+ISZQ?"H:Z((@7?J/$9,0=?DULI'AQJ%O^5G
MGSS)2X\X>8IH0_Q?H^T-%7O2O3'B`:XZ3)D%S-,+\S:'?_EIY^T-="U">>*_
M*5@E8L2/5$;(?$-RR=V'&S8SARBB^E5ZY07?!L=<*0W@5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__1]4XJ[%78J[`K
M53A"-W<L`*7<C3IC:ANN%6JXE;:+_P"WBAY[YX_.;0M`9M.TU?TMK;_#'9P?
M$%8F@YD>_;)QA;AY];&.T=Y)%HODKSEYX(O//]PT&F5]2UT:W/IU/8R4\!C(
MUR:(89Y=YFGI6@^5]!T"T^JZ19QVL7?B/B/S;J<AQ.?CPQB-@F=:#M08)-@Y
M;O'O+VER>>OS6U#S/=_O-"\O2?5M(_E>:*@+#Q59/4?_`(#+Y4(NIQ1\;.9G
MZ8O8PN4NX74Q0[%78J[%75-?;&U:K@5P.$JW7`2KJXVKJXJU4UQ1;>%+L5=B
MKL2KJXJZN`J["KL5<33%75P*X'"BW8I=BKL5=BK_`/_2]4XJ[%78JUW.*.K'
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MUVQH1V4^!]\Y_M?MV.&0QXO7E_B<O'C)&ZA97?FN6[B]:)!;%AZA`&P[[US'
MTFHU^3+'Q(F.)F1$!*?S#UW5KE?\)>6:MKFH*!<SC[-I:ML\KM^RS+58\Z^.
MPW=5J,A/HC]3)?*7EVT\NZ!9:/:#]U:QA6>E"[]7<^[-5L9'=OP8ACCPA.:8
M&UV*NQ5V*NQ5:[A=SLO<Y7.8B+/):M*KKS1H]NQ5IN3+U"`M^K-1F]H-'C-&
M=G^BV#%)3A\W:-(P4R%*]"P('WY3B]I=),UQ).&2;17$4R"2)@Z'HRFHS=X<
ML,@XHGB#`BEX\<M#'FQS4_-PLK^6U:W+>F0`U>M17.1[0]I/`RF%<F^&*TUT
M74_TC9"YX>G5F7B=^AIF[[(UWYK%XGFUY(T4>#FSMK#>%+L5:)Q1=,#_`#1_
M,T>1ETX_4C>"_,HV8+Q](*?QYY9&-N%K=7X0"[\K_P`RQYYAU"061LQ8O&A!
M;D6]16/;_5R,HIT6J\4,Z[Y%S`WBE"ZKJ-KING7&H7;<+6TC::9^M$05)Q`M
MADD(BRPRW_.W\NY[B*"/429)W6.-?3<59V"CMXG)^&7$':.([`L\4UKE8<T-
MX4NQ5V*NQ5__T_5.*NQ5V*M'`50>JP1S6,R2(TB\2?339B1OMF)KL0GB(]7+
M^!E$[L#U2T1(UDCL9[8#^\>?H?#[L\T[4TO!`3$,L=_JR.9C/$*++_*MX]SH
M\1<\FAK$3_J]/P.=O[.ZDY=*#+U&/I<;)$`M^9T0Z'=[#91M_L@,L]H<,?R<
MY5O'_BA%C`[O/*G/)>CL(Q[F?>3E4Z(AI0\WJ?&ASU#V7QQ.D!K>W"S;2I-+
M^<6UE/<?[Z1F'S'3-UK<GA8)2'\$92^QA`67GVFQBYN99Y;::[J>1$/4.36I
M^C/,=#$Y\DIRCER'_:W,G*A09IID,D.CJMI"\4I!X13&K*Q/5OEGI/9<.'`-
MI_\`)3ZG#D6]"\OVFEB:4'U;^\?U+V[;=I'^?95^RBYLB;:(8Q%-0H&!L<Q-
M-L4-<CT[XJ[D0*[4\<%I=R)Z80BVP?'%6+>==5DA6.RB;B91RE(Z\?\`,9QO
MM5VG/"!BA_&.*7VN3AA>[%]/TZXOKD06XJQW)/0+XDYQ6@T6353X8\W+E(1"
MMJFA7^G+RG4-$33FNZU]ZYE=H]BYM+$&7+^=&V,,O$B_*VKRV5[';R-_HT[<
M2IZ*QZ4S-[`[6EBS"$C>.35FQAGX&>H.$!3']2\I0WM[)=-.R-*02`*@4%/'
M.7UWLS#/D,R3<OQ_-;XY>$)EI.F)IUI]71RX#%@QVZYM^S-"-+B\,<N)A.?$
MC>G3-@UM\C]W7%2[GA26B32N%%,)_,G\LK3SPFGI<7SV?U`RE."!^7JA0:U(
MZ<1DXR(<75Z09@+7?EM^6EKY'BOH[>]>\%^T;L70)Q],$"E"?YLC*5HTNE\+
M8,V]\C;F4US/TX58U^9!)_+_`,Q`_P#5NN?^338P^IQM4:QRO^:7R!H>^NZ;
M7_EK@_Y.KF7+D\G@^L>]]R+L!3Z<Q'M(\G%C7;ID2M%W(],(5L,:8VD-XVK_
M`/_4]4XJ[%78JT>N1-I4+L5MY1\1)4TX[-T['QRC5Q)QRK^:>O"L.;"=5:5]
M/DYVUZM-PT[50;_M;9YWVA&1Q5Z^?\60S<N!-M:?YKT?RSY9OM3U6<16T,I*
M@?:=N`/%!^TQXYO_`&-LX)Q[I_[T.+K<@QBRQOR?YO\`.'F^TU[6-0M_JOEO
MTEBTR$"E7$H)8U^)RJ_:=?@_ES;^T7^(Y/\`-_W<7"[/S3R3L\E;/(.@>@X:
ME;T#R;_QPX_^,C_KSU/V5_Q/_./^]<#/]15O-,G#0KG>E0J[>[`9D>T&0QTL
MJ_B#'%]3$-%+K'(4ANI:D?%;'B!0'KG!=DB0A(@2_P`S)X;E9&=Z:K"SAY+(
MIINLIJ_^R.>FZ&)CB`(^<N-PY(L"F9;%QQ4K30C?%$2^:OS(_-GS_I/G;6-.
MT_4C#:6D_"WB$434'!32K*3^UF1&`IY_4ZZ<<E!6U7\Z/S"UUA;^5+:;ZM;P
MHL]U!;F65Y`H]1R:-&B\NB\>6`0"SUV68]+%+'\XOS)L;HLVK23,K4>WN$2E
M0:<6'$,N^2G$='$&NRQ.Y?37D3S0GFCRII^MJHC:ZC/JQCHLJ$HZC_9+F/(/
M2Z?+XF,22?SQ$ZZE#(0>,D7%3VJ"21^.>;^V&.7YB,OX?#$?]G-V>GEZ4/Y6
MU2"ROF$PI#<`+ZG\I'C\\Q?9G7PP9B)#Z_XF6>)(9M<6UM?6KPR4:*44J#^(
M.>BZC3XM3CX)>J+@@D%`VWE/18"&]$R,I!!=B=QWS7:?V?TN(\K+9+(2G'0#
M-[36-V$Z]KVK6VKW$$-P4B3CQ4!32J@]QGFW;';6IQ:B4(RH!S<>($,@\L7M
MS>:4LUP_J2%V!;8;`^V=7[/ZK)GTW%/ZN)Q\D0#3P?\`,_\`,?\`,;RWYXU#
M2[75C'9`I-9J8HB!%(@8+4I4\3R7.FC$<+S.LU>3'DH/4_R;\VWWF;R5%>ZE
M+ZVHPS2074E%4L5-5)``'V&7*IBG9Z#.<F/=CWY\^?M>\L_H>WT.[^JSW7KR
M7!"HY*)P51\8;NS881<?M352QT(\U7\B/,WF[S-9ZIJ&O7QNK>*1(+53&B#D
M`6<_"H\5QD&79N:>0$R*S\^_.WF7RQ%HIT2\^J&[:X$YX(_((J<?MANG(X81
MM':.HGCY+OR#\Y^9?,]MK+ZW>&[-I)`L%41.(=6+?8"^&"87LS//)9D7IFMZ
MK:Z3I%[J=T:6]E"\\OR1:T^G(1%FG8Y,G`"3T?+&K_G9^8>J7K/;WYL8W?\`
M<VMLBGC4_"M2K,VW7,@0#S>;79)3V*:7OYL?F';:%?Z-YILGEM=3M)+>*>:%
MK>13(A4,&(577?\`EY9$@-YU>24)"7\TO.]!!_3NFG_E[@[?\6C+)<G5X?KC
M[WW$20!3[\Q2]F-@^?OS'_/W6(M;N-,\L-'%:6KF&6]90[R2+LWIDG@$!VJ5
MRV,'2ZOM(@U%@C_FK^9LP-W^F;EHDKRD2-/37Y\4*TPT'`&IST3;)_)GY_>:
M;35K6#S#,E[IDSK'/*8PDL88@!P4XJ14CMC+&')TO:4^*I/I42Q^B9>0].G+
MGVXTK6N4</1Z'B%6_P#_U?5.*NQ5V*N."K58X#*5)H#M]X[8)QX@1WK=,(U*
MWMHS/;O=:@[+R4*:M&33:N^X\,\_[2Q1'%#BEQ?S?"G_`+OZ7*QRY),GE71?
M-%J-(UDLL<%U%>HJG@7,896C))Y`,&_9^+,CV/U0QRGCD>&9(E'_`'S1K],,
MH%[LXUVUM;3RU/;6T:P00QJD42#BJH"!10.@IG1>T&^BR>Z/^[BC#'A-!Y[G
MD+L"'H'DX_[A(]_VW_7GJ/LK_BG^<?T.'F^I!^=-1C%FMDA#23,&<`C95WW`
MWZC,/VLUH&,8H_5(]_\`O66".]E)=(@B*+$TU[#-(].,(XIN:`GY9S_96$</
M"3*,B?I\.<_]DV9),_AC].-$J6*BA9MR:=SGIN./#$!Q"J98AQQ06F44Q2-G
MQW^;O_DR?,'_`#$_\RDS)@=GD=?_`'I?2GY2V%G;?EYH?U>%8C-:1RS%!0O(
MXJS,>['*,AW>CT,0,0I\_?GUI=OIWYCW9MXQ''=PPW3(HH.;@JY_V7"N70Y.
MA[2B(Y2`]B_YQUE+_ETJGI%>3J/IXO\`K;*\O-V_91O#\7H&KZ5;ZE:^A)52
M#5'7JK>.^:GM3LV&KQ<$MC]7XWB[6$S%@&IZ/?:?(5N(SP_9E4$HU??I7VSR
M_M'LG-I95($P_GTYL<@(7Z7KFI:>1Z,G.']J*0DK3V\,L[-[8S:4U$^C^9Z?
M^)E)$L0(Y,XTC7+74HN41X2#[<34Y#W^6>D=F=K8M9"Q0G_J=^K_`'KB3QD)
MF-^O7-JU/.?-'_'>NOFO_$!GDGM`/\+FY^+DRCR7_P`<1/\`C(_Z\[?V5-Z/
M_./Z'&SCU/&O^<G=$"WNC:VBG]ZDEG,0#U0^I&2>G1I/\USK<4C1>=[7AR*I
M_P`XPZQ2?6]&<@AA%=Q`D5VK&^WT)7(YD]D9.88O_P`Y":P;[\PI;4,#'IEO
M%`*$$<F'JOT[_'3_`&.2QC9P^U)\64CN_4]L_);1!I/Y=:4K*5FO%-W+4$;S
MMR44/A'P&53.[NNS\0AC'>6!_P#.48'H^7/]>Z_XC%D\1<+M@[!?_P`XN_[P
M^8CW]:V_X@^#(GL8;29K^>ET]O\`EAJW#K,8(C\FG2OWC(0YN5VB:P'X?[IX
M+^2%A;WGYEZ2EP@D2+U9@I_FCA8K]S4.7SV#I-!$','T=^:-C:77Y?Z\+F))
MA#9SS1<Q7C(B%E85Z$'*(\WH=;$'#+^J^1=`_P".]IP_Y>X/^3JYD2Y/*8OK
MC[WVY?P33V$\$$GI32QND4I%>+,I`:GMF,"]B8V*>"?]"P:L1\?F"'?=B+=Z
M[]?V\M\1T_\`)!OBXO\`8_M>SMI/EC2?+9TJ=+>TTA83"Z2E8XRO&A)+'\>6
M0W)=I*$80(\GQ7<!5DDC0UC5GXD="`=NF9`&SR4OJL=[[$6>7_E4YN.1]7]!
M&3GWY?4ZU^_,;J]4/[B_Z'^]?__6]4XJ[%78JT:UQ5`ZQK%AH^G7&HZA,(+.
MV0R2R'P`K0>)/;#3"<Q"/$7G'D/SWK_GZ^U<QVC6.C6\E=.OXVHVU!Z4BG:5
MF'Q']E,Q>T-$<D/3+AE[G&T6L.21VV334]"\P+())E-R12DJ'D:>%-CGF_:'
M8FL.2Y#B_I>B/^^=Q'($+//KR6[0W#3B&E'#\B*=.I%,Q<^35QQRC/Z-OYC.
M/"EV:4BBV%,+2ZUP0B*T:;T`33TPQ^?09M])J-4,?#B^C_,_WS7DHE7M=!UV
M:7U8X620GEZLAIOX[FN9&'L35Y)B5;_YGI_V3&60`,OT32KVS5WN[EYY7_9+
M$JOR!SONRM%EP1_>'C)\N%Q92M-17D/#OFVZL%V25QQ07'IBE\=?FY_Y,K7_
M`/F*_P"929DPY/(Z[^^+Z;_*W_R7GE[_`)@8O^(YCY.;T>A_N0\'_P"<CC_R
M$-?:Q@_XE)ET8V'1]K?WKTW_`)QQV_+Q_P#F/F_XBF0R_4[3LG^Y^+U&214%
M68*HZD[#\<QR0.KLZ4^5O=1,%99HS\+@$,/<'(>C,"#ZHI%AB/F/RS%:Q->6
M0I&O][#V`\5SA.W^P/"B<L.7X_I.3BRVD.GWDEG>Q3H:-&RUIT*DT(/T9R^B
MU,L.2,XENR"P]2C(*@CH=_OSVD2L6X$GG7FC_CNW7S7_`(@,\E]H/\;FYV'D
MRGR7_P`<1/\`C(_Z\[7V4_Q3_.+C9_J8_P#G=HGZ6_+K4@JUFL@MY%X@PFK?
M\)RSJL9HNJ[0Q<>.G@'Y+ZTND_F)I<KN%ANO4M9B30<94/&O^S5<NF+#HM!E
MX,EI3)ZWF[S\5!)?6M2('LDTM!_P,>`"HJ1XF?XOLVW@2"%((QQCB4(B^"J*
M`9C2>KC&A3PW_G*3^X\N?Z]U_P`1BRW&Z3MCD%3_`)Q<_P!X?,7_`!EMO^(/
MCD3V-RDRW\_/_)8:A_QEMO\`D^N0AS<KM+^X/X_B>+_D%_Y,[3_:*Y_Y,MEV
M3DZ;LO\`O@^BOS(_\E_YB_[9]S_R:;*(\WH-7_=2_JE\?:!_QWM._P"8N#_D
MZN9,N3RF'ZQ[WW&31:DT`ZG,5[0<WA?YF_G[):W,^D>5.#21%HY]3<<E!!HP
MB4]:4-7^S_+ET8.GU?:-7&/-Y_Y=\B^??S$O?KT\LTEGRI)J=ZY90!U$8-"W
M^P''_*R1V<#'@RYQ98)/&8YI8R>7ILR<NE>)*UI[TR?1P)QX33[`'_DG?_!>
M_P"Q+,7J]:!^X_S/]Z__U_5.*NKBKJXJI3SQ0QO+*>,<:EG<]`%%23]&(")<
MK>"7VHZU^<OF%])L6:P\H:=(9)[D;M*>B$]N9'V$_8_RLMY!TW%+4R(_@#VW
M0?+^G:%I,&F:;"(;6W0*BC8D]V8]V;N<IEZN;ML>,0B!%,>)I@X6P)5YG`.A
MW=0#\(_XD,TO;\!^4F2.@_W0;,7-YSGDPY.==,\\IR1Q:"LDC`(K/R8[``'/
M4/9>(.E#A9SNGD4JR('3=3T/B,Z,!J!M4IAI6\:5V%7'%!<>F*7QU^;G_DRM
M?][K_F4F9,.3R.O_`+TOH/\`*+S?Y=NO(NE6B7T275A;I;W4$CJCJZ"AV)W&
MW7*9Q)+O=%J(#$`2\&_.GS#8Z]Y^O+BQ<2VMO%':QS*:AC&#R(_V;4R^`H.F
M[1R">4D/:_\`G'B!X_RXCD(VGNYY%]P"$_XTRG,;+N>RHUA37SC;WMOJ'J^H
M[6]Q3@*[!@*$?AGFOM1ARPRV+\,Q^IWF$BEGE?7H]/D,%SM;S-RY]U:E/QRC
MV?[;&F/!/>$DY<5\DTU[S/ISV$MM:OZTDRE:@$*![G-[VWV[A.&6.%RE+W</
MWM.+&;MB5O;R7%PD""K3-P7^N<!I<$LLXQC]3EY#L]4B`5%4=@!]VV>VQC0`
M==([O._-'_'>NOFO_$!GDWM!_C<W.Q<F4>3#_N%0?Y;_`*\[;V5'^!_YQ_0X
M^H'JM.+RUAO+2:TF7E#.C1R*>ZN*'.D!W:)1L/B/6]+N=#UV^TQF(FTZX>$2
M#8_NVV8?,;C,R,@0\9D@83(9[_SCSHB:AY^6[E%4TRW>X44V]1J1+_Q-F_V.
M1F:%.?V9'BRWW!]2US%+TF[PC_G*/>'R[_KW7_$8LOQ!TG;'(*G_`#B[_O#Y
MB_XRVW_$'P9$]C<BS?\`.ZQ>[_++6%0$M`L4Y`_EBF1F/T*"<A#FY?:$2<!`
M_'J?/?Y/ZW9:+^86E7M\XBMOWD,LAZ+ZT3*I/TE<OF+#H]#,0S"WT#^:OG+R
MU9^1M6MY=0A>XO[26WM88W5W=Y4*KLI^SONV4QB7>ZS-`8B+^KTOEG0=M=TT
MGH;N"G_(Q<R)#9YK!']X!YOKC\T]3N],_+[6[RS)%PEL51A^SZC*A;_8JQ.8
MT>;U6JD1C-/DC0DTU];T^+4VXZ8]Q$MXX_WUS',_2!OF16SRV("4P2^N]1\W
M^3O+GEWZV+N!+""(?5H+=E+,*?`L:J>K9CT27J9ZC'#'L>CXXN',DTL@6@D9
MGIUIR)-,R:H/)R()OS?7PK_RIT_^`]_V)9C=7JP?W%_T/]Z__]#U3BKL4-5Q
M2\F_/'SM-;6]OY0T=N6L:W2&7C]I(9#P"^S2DT_U<LB'5]H:@@<$?JDSCR5Y
M.L?*GEZWTJR`Y(O*XFI0R3,*NY_V709$RLN9I\`QQ`ZLB'3(N0[%4I\S?\<*
M[_U1_P`2&:3VA'^!S[MO]T&>$U*R\KU/6;#354W,E97VBMD^.5SX*@^(YYIH
M>S\VH)CC#?J-5#%N=RS3R?H6J7%G#<ZU,`BDO!I<9_=Q,34>J1_>2K_P*YZG
MV5IHX,'!$VX!)F;+,U6@`Z4VV\,V0Y!L([E^%+L5=BKCB@N/3%+X[_-O_P`F
M5Y@_YB=O^129D0.SR.O_`+TLI/Y&ZEJ'E+1_,'ER7G<7=I%)=64C<3S(JQC;
M_C4X#,6YA[/E*`E$I)I'Y)?F#J%\D$U@;"'E22XF9:*/$4)KDC,4TX^SYRE1
M?3WE/R[:>7?+UEHMIO#91A.7=F.[,?\`68DYCR.[TF+%P1$49J.G6]_;-;SK
MR1NGB#XC,+7:..HQ&$FV$J+#+_RCJD$A,(^L)V(/Q?=GGNL]F,^,^CU1_'DY
MD<XI#1>6=;E:GH</\IS3]68N+L#4S.S+QHAE6@>6H].8SS,);D[!NRCP&=GV
M-V##2^J?JFX^7+:>#;.D<>V&ZYY<U2ZU6>XA13')3C4T.RTSS[M;L'-FSF4>
MKEPR@!/?+5C<6.FB"X`60,Q(!J*$YU'86CEI]/P2Y\35EE:;9N::G@'YL_D_
MYIUKSM=:OHEO'):WL<32EG"'U43@VU.X49;&5.CUV@EDR7%D?Y%_EUK_`)5N
M-6NM:B2*6Z6&.W5&Y?"I<O7;Q*XR-M_9FDEBLR>N'*W:$/*/SV\B^8O-<6C#
M185E-FTYG#MQIZ@0+_Q$Y;"5.L[1TLL@%+_R)\C>8O*EMJZ:U$D37DD+0A&Y
M5$:L&K]^1F679VF.,&WIFH6-O?V-Q97*A[>YC>*9#W1QQ(^XY`&MW/G`2B8G
MJ^7_`#5^1/G/3-3D32[8ZE8,Q^KR(0'53N`X-.F9$<CSF;L^8ELR/R7^06K.
M)-0\R@!HXG^JZ<'+%I"OPF1OV5!_9R)D'(Q=G2_B8]I7Y&?F'!JME-+9PK'!
M<12R,)?V4<,U-O`8>-JAV=D&2QR?2NNZ1:ZSH]WI5VO*WO86AE'>C"E?HZY3
M=%W\X`Q(?+^O?D=Y]TZ]DAM++])6P;]W/"5^)3TY*Q%,R!D%/-Y>SY\6R;^3
M?R$\UZA?Q-KR_4-,B8-+&7K*PZ\$45"U(^UD3(!NP=G3E]7)+;O\AOS`%U<"
M"RB:#FPB/JBI6IXGIX9,Y135+LV?%71]"QZ1J9_+4Z.8E&I_H@V?I<OA]?ZK
MZ5.7ASS')W>@\+]UP_T>'['_T?5.*M'!:5DAHI]N_P`M\D&N>[P?\G].?S;^
M8.M^=M17G':S,EDK[@2.2%V_XJA5?]DV6&6U.HT4?%RF9>]`^.5NY%M\L"4#
MJVO:1I%F]YJ5U':VZ"I>1@.G@.I^C"`UY,L8;R-/*]2_,;7_`#N\VC^2;,QV
M!%+O7;H<8D4&IX>)RO6:;&<9&7Z7"&IG,UC"_2-#T?RXCBT8ZAK,@K=ZM..3
MU/:('["_+.)[6]H,>*'A:8</])V&ET0B>*6\F<^5=3LX],6*28+*'9G#G?<U
MS*]G.TL$,%3F!-R,D22R..9)%5T8,K[J1TIG60F)`2CZ@T$*F35V*NQ5HXH+
MB?QQ2'QY^;?_`),G7SXW(H/^>:9D@;/(:[?*7TS^5I)_+SR]_P`P,-?^!RF0
MW>FT9'A"F4TKD');"D8JZAP&T.XXTD.XFF-*X`TQI74\<2%+N/OA5W'WP(<!
MA27<<5:52.IQ0!LN(Q2MXG%#84XE(<17%7<3A5KB:UKD4-\3A2UPWZX5;"[;
MG`KN/W84-<3XX$E<!BK_`/_2]4XJTW4#"I8KYF\\Z;H'F;1M+U!Q#!JD=P1<
M,:(KQ>GP#'_*Y-A`<;)J!"0!ZJ_E'ROHGEVWO1I3_P"B7]P;PI4%49U4,%/\
MOPXTG#CA`;%K7_S#\GZ$A.HZE"DBBHA1@[GY*M<>$K/50@-R\ZN?S_O-5NVL
M/*&AS7UPQ*QR25IX!BJ]!_K9+@<&7:!.V,6K6GY2^8_-5[!J_G_46D"?%'I-
MOLB`[\2?Z8\5+#23R>K*?@](7RGI<5A#I]HIM+&(46W@^!=NYIUS6ZW11U`J
M1E\W:XJQ<@H?X)TD=&DVZ?%FE_T)Z;GZO],Y'Y@N_P`$:5_-)3PKB/932CEQ
M_P"F0<Q3NSLX[6WBMXJ^G$`JUZT&=!@T\<4!$7Z6HR)1&9"'8J[%7'%6L:6W
MG?F#\CO)^NZQ=ZM>-<?6;Q^<O"2BU"\=A3VRSCVIP,FAA.5EFNA:-:Z+I%II
M5IR^K6<2PQ<C4\4%!7($N7CQ"$:"8#`V!V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_T_5.*M$5PH+`_P`U_P`M(_.^F6Z1
M3+;ZC8LS6TKUX,'%&1Z;T-!DHEP];I?%`HT0\LM?R2_-E%%J-5$%K]DTNI.`
M7_5!KD^,.M&@SC:]O@RGR]_SC=H5O(MQKU]+J$U:M$E42O>K&K-D?$<G'V7$
M;R/$]3T7RQH6BVX@TJRBM(P*?NU`)^;?:.0,G8XL,(?2*3((*4P-A%MTP$!(
M=3"%;IBKJ8J[%78J[%7'%74Q4NI@6G4PK3L44[%+L5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_`/_4]4XJ[%74&*NH,5=08J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
978J[%78J[%78J[%78J[%78J[%78J[%7_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
